C2936279||switching
C0069751||oxcarbazepine
C2725262||eslicarbazepine acetate
C1518527||observational study
C2936279||switch
C1708470||immediate-release
C0069751||oxcarbazepine
C0069751||oxcarbazepine
C2725262||eslicarbazepine acetate
C2725262||eslicarbazepine acetate
C0069751||oxcarbazepine
C2725262||eslicarbazepine acetate
C0035363||retrospective
C2603343||single-center study
C0013203||drug-resistant
C0014547||focal epilepsy
C1708470||immediate-release
C0069751||oxcarbazepine
C2936279||switched
C2725262||eslicarbazepine acetate
C2936279||switched
C0036572||seizures
C0069751||oxcarbazepine
C1299582||unable
C0069751||oxcarbazepine
C0041755||adverse events
C0282574||Adverse Events Profile
C0282574||Adverse Events Profile
C0282574||Quality of Life in Epilepsy Inventory 10
C0282574||Quality of Life in Epilepsy Inventory 10
C1443086||alertness
C0037585||Test Battery for Attention Performance version 2.3
C1261322||Assessments
C2936279||switching
C0069751||oxcarbazepine
C2725262||eslicarbazepine acetate
C0936012||analysis
C0043210||women
C0025266||men
C0243095||mean age 36 years
C2936279||switching
C0069751||oxcarbazepine
C2725262||eslicarbazepine acetate
C0282574||Adverse Events Profile
C0282574||Quality of Life in Epilepsy Inventory 10
C1443086||alertness
C0282574||Adverse Events Profile
C0184511||improved
C0282574||Quality of Life in Epilepsy Inventory 10
C0184511||improved
C1443086||alertness
C0184511||improved
C2603343||single-center study
C2936279||switch
C0069751||oxcarbazepine
C2725262||eslicarbazepine acetate
C0013203||drug-resistant
C0014547||focal epilepsies
C2825142||resulted
C0041755||side effects
C1443086||alertness